Comparative Pharmacology
Head-to-head clinical analysis: AXID versus PEPCID PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXID versus PEPCID PRESERVATIVE FREE.
AXID vs PEPCID PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive, reversible inhibition of histamine at H2-receptors on gastric parietal cells, reducing gastric acid secretion by blocking the H2-receptor-mediated activation of adenylate cyclase and subsequent cAMP production.
Competitive antagonist of histamine at H2 receptors on gastric parietal cells, inhibiting gastric acid secretion.
300 mg orally once daily at bedtime or 150 mg orally twice daily. Max 300 mg/day.
20 mg intravenously over at least 2 minutes or as an infusion over 15-30 minutes every 12 hours; alternatively, 20 mg orally once or twice daily.
None Documented
None Documented
1.5-2.5 hours (prolonged in renal impairment: up to 4-5 hours if CrCl <20 mL/min)
2.5-3.5 hours (normal renal function); prolonged to 20-30 hours in severe renal impairment (CrCl <10 mL/min). Clinical context: dose adjustment required in renal insufficiency.
Renal (60% unchanged), biliary (30%), fecal (<10%)
Renal (65-70% unchanged by tubular secretion); minor biliary/fecal elimination (<30%). Clearance correlates with creatinine clearance.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist